First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801 Authors: Chris Brearley, Sam Francis, John Reader, Judi Proctor Published: 2026 ABSTRACT AbstractAimThe purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants.MethodsThis first‐in‐human study randomized 95 male and female participants. Parts one and two were double‐blind, placebo‐controlled escalation designs, investigating single (5, 10, 30, 75, 150 mg) and multiple (30, 100, 75, 140 mg/day) doses of SDC‐1801 or matching placebo. Part three evaluated the FE of 75 mg SDC‐1801 in an open‐label, crossover design.ResultsThere were no deaths or treatment‐related serious adverse events (AEs) following SDC‐1801, up to 150 mg; no treatment‐emergent AEs (TEAEs) were severe with non‐related headache most frequently reported. PK showed low to moderate variability and no consistent dose‐exposure relationship; T max occurred 3–5 h post‐dose with a geometric mean (GM) t 1/2 of 15.2–27.0 h. Bioavailability appeared solubility limited, with lower exposure from the higher strength capsule and modestly higher exposure in the fed state. No safety stopping criteria were met. PD assessments demonstrated anti‐inflammatory activity, with IFN‐gamma induced protein‐10 (IP‐10), high sensitivity C reactive protein (hsCRP), and signal transducer and activator of transcription (STAT3/5) phosphorylation reductions with increasing exposure giving greater inhibition. At the highest exposure, there was a clear reduction of IP‐10 levels at pre‐dose on day 9, which rebounded following drug withdrawal.ConclusionsSDC‐1801 was well tolerated to 150 mg; all TEAEs were mild or moderate, with unrelated headache most frequently reported. The PK profile supports the potential for a once‐ or twice‐daily regimen, with evidence of target engagement for both TYK2 and JAK1.Keywords: autoimmune, first‐in‐human, inflammation biomarkers, pharmacokinetics, SDC‐1801, tolerability, TYK2/JAK1 What is already known about this subject The Janus kinase (JAK) family of kinases (JAK1, JAK2, JAK3 and TYK2) indicate the role of JAK signalling pathways in several autoimmune diseases, such as psoriasis. The Janus kinase (JAK) family of kinases (JAK1, JAK2, JAK3 and TYK2) indicate the role of JAK signalling pathways in several autoimmune diseases, such as psoriasis. SDC‐1801, a potent and selective small molecule TYK2/JAK1 inhibitor, has potential for an improved safety/efficacy profile compared to other JAK and TYK2 inhibitors. SDC‐1801, a potent and selective small molecule TYK2/JAK1 inhibitor, has potential for an improved safety/efficacy profile compared to other JAK and TYK2 inhibitors. What this study adds Single and multiple ascending SDC‐1801 doses of 5–150 mg were generally well tolerated. Single and multiple ascending SDC‐1801 doses of 5–150 mg were generally well tolerated. Geometric mean half‐life ranged from 15 to 27 h after single and multiple SDC‐1801 doses, supporting the potential for either once‐ or twice‐daily dosing regimen. Geometric mean half‐life ranged from 15 to 27 h after single and multiple SDC‐1801 doses, supporting the potential for either once‐ or twice‐daily dosing regimen. There was evidence of target engagement for both TYK2 and JAK1. There was evidence of target engagement for both TYK2 and JAK1. INTRODUCTION Janus kinases (JAKs) are a family of intracellular tyrosine kinases. 1 The four members—JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2)—associate with type I and type II cytokine receptors and function in pairs to transmit extracellular signals by phosphorylating, thereby activating the signal transducer and activator of transcription (STAT) proteins, and regulating gene expression involved in cell proliferation, differentiation and immune responses. 2 Dysregulation of JAK–STAT signalling can lead to excessive or aberrant cytokine activity, contributing to chronic inflammation and loss of immune tolerance. Aberrant JAK signalling has been implicated in the pathogenesis of numerous inflammatory and autoimmune diseases, including rheumatoid arthritis, inflammatory bowel disease, psoriasis and systemic lupus erythematosus, making JAK kinases an important therapeutic targets in these conditions. 3 The success of JAK inhibitors in the clinic (e.g. tofacitinib and baricitinib; small molecule JAK inhibitors with limited but different selectivity within the JAK family of kinases) has paved the way for newer, more selective pharmacological agents of this class. 4 , 5 Recent efforts to generate more selective inhibitors targeting individual members of the JAK family have reached fruition, exemplified by, for example, upadacitinib 6 and filgotinib 7 targeting JAK1 or, for example, deucravacitinib 8 and zasocitinib 9 targeting TYK2. JAK1 is a key mediator of inflammatory and autoimmune processes by transducing signals from a wide range of cytokines involved in innate and adaptive immunity, including type I and II interferons (e.g. IFNα and IFNγ), interleukin‐6 family cytokines (e.g. IL‐6, IL‐11), and several common γ‐chain–dependent cytokines (e.g. IL‐15 and IL‐21). 10 TYK2 associates with receptors for cytokines of the p40 sharing IL‐12 and IL‐23 family, the type I interferon family, and the IL‐10 family. The specific targeting of IL‐12 and IL‐23 pathways (leading mainly to polarization of T helper [Th]1 and Th17 cells, the two most prominent proinflammatory T cells) is of particular interest in the field of inflammation and considered most relevant for translation into clinical efficacy, as shown by the treatment success of anti‐IL‐17 (e.g. secukinumab, brodalumab), anti‐IL‐23 (e.g. guselkumab) and anti‐p40 (e.g. ustekinumab)‐directed biologic therapies. 1 Taken together, this suggests that combined inhibition of TYK2 and JAK1 could provide broader and deeper clinical benefit in a number of inflammatory diseases. 11 The dual TYK2/JAK1 inhibitor approach has been clinically validated by molecules, such as brepocitinib, in diseases including plaque psoriasis, psoriatic arthritis, ulcerative colitis and alopecia areata. 12 , 13 , 14 , 15 , 16 SDC‐1801 is a potent, selective small molecule TYK2/JAK1 inhibitor that is currently in development for inflammatory and autoimmune indications. SDC‐1801 is an adenosine triphosphate (ATP) competitive inhibitor of TYK2/JAK1 with lower potency over JAK2 and JAK3. In biochemical assays, the inhibitory concentration 50% (IC50) of SDC‐1801 for TYK2, JAK1, JAK2 and JAK3 was 1.3, 22.2, 79.9 and 214.3 nM, respectively. However, as previously observed in JAK drug discovery, the selectivity profile is more meaningfully assessed by measuring direct activity of SDC‐1801 on pathways involving combinations of the four JAK proteins in whole blood assays. In both mouse and human whole blood, SDC‐1801 demonstrated potent inhibition of cytokine signalling dependent upon TYK2/JAK1, TYK2/JAK2, JAK1/JAK2 and JAK1/JAK3 heterodimers, while demonstrating minimal inhibition of signalling dependent upon the JAK2/JAK2 homodimer. SDC‐1801 has demonstrated efficacy in mouse models of rheumatoid arthritis, psoriasis induced by IL‐23, a cytokine that signals through TYK2, and imiquimod‐induced psoriasis. Finally, a pharmacodynamic (PD) model using human skin demonstrated ex vivo TYK2 target engagement of SDC‐1801. The strong selectivity of SDC‐1801 was also established using a panel of 369 kinases where SDC‐1801 demonstrated significant inhibition (>90%) only against TYK2 and one other kinase (activated CDC42 kinase 1 [ACK1]). Follow‐up IC50 determination showed that SDC‐1801 had 35‐fold selectivity for TYK2 relative to ACK1. Preclinical studies suggest utility of ACK1 inhibition in the treatment of cancer and inflammatory diseases; however, clinical validation is currently lacking. In addition, SDC‐1801 was tested at a single concentration of 10 μM in a CEREP (Eurofins) panel of 44 receptors, enzymes and ion channels, showing low activity (<50% inhibition) in all but two assays: SDC‐1801 inhibited the binding of an agonist radioligand to the human cannabinoid type II (CB2) receptor by 54% and inhibited binding of an agonist radioligand to the human Kappa receptor by 52%. However, these findings did not translate into meaningful activity in functional agonist or antagonist assays against either target. The nonclinical good laboratory practice toxicology and safety pharmacology studies indicated that SDC‐1801 has the potential to have an improved safety/efficacy profile compared with other JAK inhibitors and specific TYK2 inhibitors. Here we summarize the findings of a three‐part, single ascending dose (SAD), multiple ascending dose (MAD) and food‐effect (FE), first‐in‐human study in healthy adults, designed to evaluate safety and tolerability of oral SDC‐1801 compared with placebo, the pharmacokinetics (PK) and PD of SAD and MAD SDC‐1801, target engagement of SDC‐1801 and potential cytochrome 450 (CYP)3A4 interaction with multiple doses of SDC‐1801 using 4β‐OH‐cholesterol (4β‐OHC)/cholesterol ratio as a marker. PK were assessed as secondary objectives in SAD and MAD and compared in fed and fasted states, and the PD of SAD and MAD SDC‐1801 were compared with identical placebo as exploratory objective. MATERIALS AND METHODS Study design This first‐in‐human, randomized, single‐centre study in healthy adult participants, conducted at Nucleus Network Phase 1 unit, Melbourne, Australia, was composed of three parts: SAD, MAD and FE. The study was registered, in April 2023, with the Australian New Zealand Clinical Trials Registry under ACTRN12623000416695p (SAD and MAD parts) and ACTRN12623000419662p (FE part). The SAD and MAD parts employed randomized, double‐blind, placebo‐controlled designs to evaluate the safety, tolerability, PK, and PD of single and multiple oral doses of SDC‐1801 compared with matching placebo, utilizing a sentinel dosing strategy for each cohort where one participant received SDC‐1801 and one received placebo on day 1. Following acceptable 24‐h safety data findings, the remainder of the cohort was dosed after 48 h (Figure 1). In the SAD part, eight participants per cohort were randomized in a 3:1 ratio to receive, in the fasted state, a single dose of SDC‐1801 (5, 10, 30, 75, or 150 mg) or placebo, such that six participants received SDC‐1801 and two received placebo. The final SAD cohort repeated the 75‐mg dose level using an alternative capsule dose configuration (Table 1). Based on nonclinical studies, the anticipated efficacious human dose levels of SDC‐1801 ranged between 30 and 100 mg once daily (OD); a human dose of 30 mg was predicted using PK simulation to maintain plasma levels above the IFN‐α/STAT1 IC50 and the IL‐12/STAT4 IC50 for approximately 24 h. Given the uncertainties inherent in modelling the oral bioavailability of SDC‐1801 in humans, a projected dose range of 5 to 300 mg was selected for the SAD dose escalation, limited by stopping rules based upon the NOAEL exposures in the most sensitive toxicology species. The 5 mg starting dose was expected to result in no or minimal PD activity with measurable drug levels. In the MAD part, eight participants per cohort were randomized in a 3:1 ratio to receive multiple doses of SDC‐1801 or placebo in either the fasted or fed state. The 30 and 100 mg doses (fasted) and 75 mg dose (fed) were administered OD for 10 days. The 140 mg dose (fed) was administered as 70 mg twice daily (BID) for 9 days, followed by a single 70 mg morning dose on day 10. The open‐label, two‐way, two sequence, crossover design, FE part was conducted in parallel with the MAD part in 16 participants randomized in a 1:1 ratio to receive two oral 75 mg doses of SDC‐1801 in fed–fasted or fasted–fed sequences, with a 7‐day washout period between the two doses. In the fasted state, SDC‐1801 was administered after a minimum 8‐h fast; in the fed state, it was administered 30 min following a standardized, high‐calorie, high‐fat breakfast. Study Schema. (A) SAD Part; (B) MAD Part and (C) FE Part. FE, food effect; MAD, multiple ascending dose; SAD, single ascending dose; SRC, Safety Review Committee; TEAE, treatment emergent adverse event. TABLE 1Capsule configuration by study part and dose.Study partDose (mg)CapsulesDose frequencyPrandial statusSAD part51 × 5 mgSingle doseFasted101 × 10 mgSingle doseFasted303 × 10 mgSingle doseFasted751 × 50 mg, 2 × 10 mg, 1 × 5 mgSingle doseFasted1503 × 50 mgSingle doseFasted757 × 10 mg, 1 × 5 mgSingle doseFastedMAD part303 × 10 mgOnce daily,Fasted1002 × 50 mgOnce daily,Fasted751 × 50 mg, 2 × 10 mg, 1 × 5 mgOnce daily,Fed707 × 10 mgTwice daily D1–9, once daily on D10,FedFE part751 × 50 mg, 2 × 10 mg, 1 × 5 mgSingle dose in each periodFed, fasted751 × 50 mg, 2 × 10 mg, 1 × 5 mgSingle dose in each periodFasted, fedAbbreviations: d, day; FE, food effect; MAD, multiple ascending dose; SAD, single ascending dose.For Further information see Supplemental information, Appendix 1. Capsule configuration by study part and dose. Abbreviations: d, day; FE, food effect; MAD, multiple ascending dose; SAD, single ascending dose. For Further information see Supplemental information, Appendix 1. Study participants and ethics Eligible participants were healthy, non‐smoking, males and females, aged ≥18 to ≤55 years, with a body mass index ≥18 to ≤32 kg/m2. Participants had to avoid prolonged exposure to the sun and other ultraviolet light sources during the study period and for 7 days after the last dose of study drug. The study was conducted in accordance with the Good Clinical Practice, the Declaration of Helsinki and the requirements of the Australian therapeutic goods legislation. The study was approved by the Alfred Hospital Ethics Committee (HREC/95614/Alfred‐2023). Informed consent was obtained from each participant before enrolment. Safety and tolerability assessments Safety and tolerability were measured by incidence and severity of treatment‐emergent adverse events (TEAEs) and withdrawals because of TEAEs, vital signs, physical examination findings, 12 lead digital electrocardiogram (ECG) parameters, and incidence and magnitude of treatment‐emergent clinical laboratory abnormalities, including haematology (with differentials), chemistry, glucose, lipids and urinalysis. Additionally, in the MAD part, suicidal ideation and behaviour were assessed using the Columbia Suicide Severity Rating Scale (C‐SSRS). Safety follow‐up was performed on day 15, day 24 and day 29 for the SAD, MAD and FE parts, respectively. PK assessments Blood samples were drawn to measure concentrations of SDC‐1801 at specified timepoints between pre‐dose to 120‐h post‐dose. In the SAD and MAD parts, urine samples to assess the amount of unchanged SDC‐1801 excreted in the urine were collected between 0 and 24 h. For the SAD and FE parts, the main PK parameters included time to maximum observed concentration (T max), maximum observed concentration (C max), area under the curve (AUC) from the time of dosing to the last measured concentration (AUClast), and extrapolated to time infinity (AUC0‐∞), half‐life (t 1/2). For the MAD part, PK parameters for day 1 included T max, C max, AUClast, AUC0‐∞, t 1/2, and for day 10, also included, minimum observed concentration (C min), average concentration during a dosing interval (C avg), AUClast, AUC0‐∞, AUC during the dosing interval limited to the end of a dosing interval (10 h in BID and 24 h in OD [AUCtau]) and t 1/2. For the SAD and MAD parts, urinary PK parameters included amount of unchanged drug excreted in the urine during a dosing interval (Aetau) and Aetau%, and CLr. Plasma and urine PK concentrations of SDC‐1801 were determined using a validated liquid chromatography tandem mass spectroscopy assay with lower and upper limits of quantification of 5 and 2000 ng/ml, respectively. PD assessments In both the SAD and MAD cohorts, blood samples were collected for exploratory PD biomarker analysis, including hsCRP and IP‐10. In the MAD part, samples were collected for flow cytometry to assess the effect of TYK2/JAK1 inhibition on the TYK2/JAK pathways, essential for immune function and haematopoiesis regulation (Figure 2). TYK2/JAK signalling pathways essential for immune function and haematopoiesis. EPO, erythropoietin; G‐CSF, granulocyte colony‐stimulating factor; GH, growth hormone; GM‐CSF, granulocyte‐macrophage colony‐stimulating factor; IFN, interferon; IL, interleukin; JAK, Janus kinase; STAT, signal transducer and activator of transcription; TPO, thrombopoietin; TYK2, tyrosine kinase 2. To assess the potential of SDC‐1801 to inhibit or induce CYP3A4 liver enzymes, plasma samples were collected to measure the concentrations of cholesterol and its metabolite, 4β‐OH‐cholesterol, the ratio being an endogenous marker of CYP3A activity. 17 Statistical analysis The planned sample size in the three study parts was 96 participants (SAD part: 48; MAD part: 32; FE part: 16). These target sample sizes were not based on statistical considerations, and no formal statistical hypotheses were tested. Data were assessed in the safety population (all participants who received a dose of study drug), PK in the safety population where at least one PK concentration was measured and PD in the safety population where at least one post‐baseline blood sample was measured for biomarkers. For the MAD and FE parts, fed and fasted states were identified. All TEAEs were coded according to Medical Dictionary for Regulatory Activities version 26.0, and PK parameters were estimated using non‐compartmental analysis methods (Phoenix WinNonlin software package, v8.4). For the SAD part, dose proportionality was assessed using a mixed effects power model, and for the MAD part, a non‐parametric Kruskal–Wallis test for dose effect and a non‐parametric Friedman test for the day effect. Time to reach steady state was assessed by visual inspection and by means of a mixed effect model on log‐transformed trough plasma concentrations, with participant as random effect and day as fixed effect. Comparison between days was performed. For the FE part, a mixed model with log‐transformed PK parameters as the dependent variable and treatment sequence as a fixed effect was applied. Descriptive statistics were presented for all continuous and categorical variables, and missing data were not imputed. Statistical analyses were performed using SAS version 9.4 (SAS Institute). Nomenclature of targets and ligands Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, and are permanently archived in the Concise Guide to PHARMACOLOGY 2023/24. 18 RESULTS Study participants Of the 96 participants enrolled, 95 were randomized and received at least one dose of study drug (47, 32, and 16 participants in the SAD, MAD, and FE parts, respectively). In the SAD part, 35 participants (20 male, 15 female) completed treatment with SDC‐1801, and 12 (six male, six female) completed treatment with placebo. In the MAD part, 23 participants (14 male, 9 female) completed SDC‐1801 treatment, and eight male participants completed treatment with placebo. In the FE part, 14 participants (nine male, five female) completed treatment with SDC‐1801, with one participant discontinuing treatment because of unrelated pre‐dose low blood pressure and one because of a death in the family. Only one participant, in the SAD part, did not complete the study because of contracting COVID‐19. Participant disposition is presented in Figure S1. All treatment groups were generally well‐matched for age, with mean values ranging from 24.8 to 32.2 years. Body mass index across all participants ranged from 18.5 to 31.9 kg/m2. The proportion of male and female participants was generally balanced, and the majority were of White or Asian descent. Demographic data are summarized in Tables S1–S3. Safety findings There were no deaths, and no serious adverse events (SAEs) considered related to SDC‐1801. All TEAEs were mild or moderate, and there were no discontinuations because of TEAEs in the SAD or FE parts. One SAE of skin laceration, because of a household accident, considered not related to study drug, was reported (SAD part placebo group). Analgesics were the most frequently used concomitant medications throughout the study. There were no adverse effects on the C‐SSRS score in participants receiving multiple doses of SDC‐1801. In the SAD part, 33 TEAEs were reported by 21 (44.7%) participants, 28 TEAEs following SDC‐1801 and five following placebo. The incidence of all TEAEs was similar between the treatment groups, with headache being the most frequently reported (Table S4). This was similar in the MAD part: 34 TEAEs were reported by 15 (46.9%) participants, 30 TEAEs following SDC‐1801 and four following placebo, with headache and myalgia the most frequently reported TEAEs. A higher incidence of TEAEs was reported in the 100 mg OD SDC‐1801 cohort; however, GM SDC‐1801 C max and AUC0–24 on day 10 were lower than exposures in the other cohorts (30 or 75 mg OD and 70 mg BID SDC‐1801) (Table S5). One participant in the 100 mg OD SDC‐1801 cohort had an elevated creatine phosphokinase (CPK) level of 237 U/l on day 6 of treatment and on directed questioning complained of mild low back pain; CPK rose to 9606 U/l by day 9. CPK decreased progressively and was within the normal range at the follow‐up visit (day 24). Moderate rhabdomyolysis was diagnosed on day 6 and mild myalgia on day 8, which resolved on day 10. Both were considered probably related to SDC‐1801, and the participant was withdrawn from treatment on day 9. There were no associated abnormalities of creatinine, hepatic transaminases, troponin T, bilirubin or urine microscopy reported for this participant. One participant (70 mg BID SDC‐1801) had raised glucose levels on day −1 and day 1 (10.9 and 8.2 mmol/l respectively), rising to 16.1 mmol/l on day 12. Moderate, unrelated type 1 diabetes was diagnosed on day 10. It was noted retrospectively that the participant had a history of elevated blood glucose and raised glucose at screening (5.4 mmol/l). In addition, one participant (70 mg BID SDC‐1801) developed unrelated mild iron deficiency anaemia (Table S5). In the FE part, nine TEAEs were reported by five (31.3%) participants. No TEAE occurred in more than one participant, and there were no apparent differences between the treatment sequences in type of TEAEs reported. Unlike the SAD or MAD parts, no headaches were reported (Table S6). One participant in the fed‐fasted sequence discontinued the study prior to receiving the fasted dose because of unrelated, pre‐dose, low BP (85/55 mm Hg on day 15, −10/−9 mm Hg from baseline), which returned to baseline by day 30 (102/62 mm Hg). During this trial, there were no platelet findings of concern, and individual abnormalities were infrequent, mild and without evidence of clinically significant haematological toxicity, even in the highest multiple dose tested (70 mg BID SDC‐1801). Neutrophil and reticulocyte changes were also small, reversible, not dose‐related and similar to those seen in placebo treated subjects (Figure S2). No additional clinically significant individual laboratory abnormalities or changes from baseline in clinical laboratory values, vital signs or ECGs were observed during the study, and there were no TEAEs related to haematology, biochemistry or coagulation findings (Tables S7–S9). Pharmacokinetics The PK parameters of SDC‐1801 for the SAD part are summarized in Table 2. Following single doses of 5, 10, 30, 75, 150 and 75 mg, median T max was observed at approximately 3–4 h post‐dose. Following peak plasma concentrations of SDC‐1801, plasma levels declined in a mono to biphasic manner (Figure 3A). Geometric mean (GM) C max ranged between 22 and 112 ng/ml; the variability associated with C max values was considered low to moderate at 27.1–61.2% coefficient of variation (CV%). GM AUC0‐inf ranged between 456 and 2836 ng.h/ml; the variability associated with GM AUC0‐inf values was considered low to moderate at 24.2–54.5 CV%. GM t 1/2 values ranged between 15.2 and 27.0 h, GM Vz/F ranged between 239 897 and 719 451 ml and GM CL/F between 10 956 and 26 404 ml/h. An inconsistent relationship was observed between the dose of SDC‐1801 administered and exposure (as assessed by AUC parameters and C max). The PK parameters of SDC‐1801 for the MAD part, day 10 are summarized in Table 3 and for day 1 in Table S10. Following daily SDC‐1801 doses of 30 and 100 mg OD (fasted state), and 75 mg OD and 70 mg BID (fed state), T max was observed between 3 and 5 h post dose on days 1 and 10 and considered independent of dose and fed status. Following peak plasma concentrations of SDC‐1801, plasma levels declined in a mono to biphasic manner (Figure 3B). GM t 1/2 ranged between 16.8 and 19.8 h on day 10. For the 70 mg BID dose, this was 13.7 h on day 1 and 18.7 h on day 10. Day 1 GM C max ranged between 29.3 and 65.7 ng/ml, and day 10 between 44.9 and 108.6 ng/ml for OD dosing and 143.7 ng/ml on day 1 and 334.5 ng/ml on day 10 following 70 mg BID dose. On both days 1 and 10, the variability associated with C max values after single and repeated dosing, between 14.0 to 61.0 CV%, was considered low to moderate. Comparison of the exposure data determined on day 10 when compared with day 1 showed accumulation ratios of SDC‐1801 for C max and AUCtau of between 1.76 and 1.9‐fold following OD dosing and between 2.4 and 2.8‐fold following BID dosing. TABLE 2SAD part – Summary of main PK parameters of SDC‐1801 (pharmacokinetic analysis set).SDC‐1801Cohort A: 5 mg (N = 6)Cohort B: 10 mg (N = 6)Cohort C: 30 mg (N = 5)Cohort D: 75 mg (N = 6)Cohort E: 150 mg (N = 6)Cohort F: 75 mg (N = 6) T max (h) n 665666Median4.13.03.13.03.03.0CV%NCNCNCNCNCNC C max (ng/ml) n 665666Mean (GSD)22.1 (1.5)24.7 (1.4)59.3 (1.5)67.6 (1.4)45.8 (1.5)112.0 (1.7)CV%46.627.141.227.438.361.2AUClast (h*ng/ml) n 665666GM mean (GSD)366.6 (1.5)460.9 (1.3)1276.2 (1.4)1576.0 (1.4)1275.6 (1.6)2746.6 (1.6)CV%36.024.132.929.246.155.3AUC0‐inf (h*ng/ml)n665666GM mean (GSD)456.4 (1.3)529.9 (1.3)1363.0 (1.3)1683.8 (1.4)1399.3 (1.5)2836.1 (1.6)CV%25.224.230.828.241.654.5 t 1/2 (h) n 665666GM mean (GSD)15.2 (1.2)16.4 (1.1)17.4 (1.2)20.8 (1.6)22.9 (1.2)18.9 (1.2)CV%17.511.918.049.516.614.4 λz (1/h) n 665666GM mean (GSD)0.05 (1.2)0.04 (1.1)0.04 (1.2)0.03 (1.6)0.03 (1.2)0.04 (1.2)CV%18.610.816.538.014.214.9MRT (h) n 665666GM mean (GSD)22.3 (1.2)23.2 (1.1)25.9 (1.2)26.8 (1.3)31.3 (1.2)27.9 (1.2)CV%15.79.617.525.816.915.3CL/F (ml/h) n 665666GM mean (GSD)10955.6 (1.3)18858.4 (1.3)22023.0 (1.3)44537.8 (1.4)107112.9 (1.5)26404.4 (1.6)CV%26.325.226.736.539.740.5Vz/F (ml) n 665666GM mean (GSD)239896.5 (1.3)445769.9 (1.3)553492.5 (1.6)1336500.9 (1.5)3536687.6 (1.6)719450.7 (1.6)CV%29.425.540.143.351.941.6CLr (ml/h) n 665666GM mean (GSD)425.5 (1.5)576.0 (1.3)464.4 (1.3)389.1 (1.4)439.6 (1.4)469.1 (1.3)CV%42.130.624.130.226.325.0 Note: AUC0‐inf is the area under the plasma concentration time curve from time 0 extrapolated to infinity. AUC0‐inf is calculated as the sum of AUClast plus the ratio of the last measurable plasma concentration to the elimination rate constant; AUClast is the area under the plasma concentration time curve, from time 0 to the last measurable non‐zero concentration. CL/F, apparent clearance; CLr, renal clearance; C max, maximum observed concentration; CV%, coefficient of variation; h, hour; λz, terminal rate constant; GSD, geometric standard deviation; MRT, mean residence time; N, total number of participants; n, number of participants in the category of interest; NC, not calculated; PK, pharmacokinetic; SAD, single ascending dose; t 1/2, apparent first‐order terminal elimination half‐life, calculated as 0.693/Kel; T max, time to reach C max. If the maximum value occurs at more than 1 timepoint, T max is defined as the first timepoint with this value; Vz/F, apparent volume of distribution/bioavailability. SAD part – Summary of main PK parameters of SDC‐1801 (pharmacokinetic analysis set). Note: AUC0‐inf is the area under the plasma concentration time curve from time 0 extrapolated to infinity. AUC0‐inf is calculated as the sum of AUClast plus the ratio of the last measurable plasma concentration to the elimination rate constant; AUClast is the area under the plasma concentration time curve, from time 0 to the last measurable non‐zero concentration. CL/F, apparent clearance; CLr, renal clearance; C max, maximum observed concentration; CV%, coefficient of variation; h, hour; λz, terminal rate constant; GSD, geometric standard deviation; MRT, mean residence time; N, total number of participants; n, number of participants in the category of interest; NC, not calculated; PK, pharmacokinetic; SAD, single ascending dose; t 1/2, apparent first‐order terminal elimination half‐life, calculated as 0.693/Kel; T max, time to reach C max. If the maximum value occurs at more than 1 timepoint, T max is defined as the first timepoint with this value; Vz/F, apparent volume of distribution/bioavailability. Geometric mean plasma concentration profiles of SDC‐1801 (Log scale). (A) SAD part. (B) MAD part. (C) FE part. BID: twice daily; FE, food effect; GSD, geometric standard deviation; MAD, multiple ascending dose; OD, once daily; SAD, single ascending dose. All participants in the SAD part were dosed in the fasted state See Table 1 for capsule configuration by study part and dose. TABLE 3MAD part – summary of main PK parameters of SDC‐1801 on day 10 (pharmacokinetic analysis set).SDC‐1801Cohort A: 30 mg OD, fasted (N = 6)Cohort B: 100 mg OD, fasted (N = 6)Cohort C: 75 mg OD, fed (N = 6)Cohort D: 70 mg BID, fed (N = 6)Day 10 T max (h) n 6666Median3.03.15.03.5CV%NCNCNCNC C max (ng/ml) n 6666GM mean (GSD)80.0 (1.3)44.9 (1.8)108.6 (1.2)334.5 (1.2)CV%22.039.920.020.9 C min (ng/ml) n 6666GM mean (GSD)28.6 (1.2)19.7 (2.0)50.2 (1.2)206.8 (1.3)CV%15.642.315.526.1 C avg (ng/ml) n 6666GM mean (GSD)46.0 (1.3)28.7 (1.8)76.8 (1.2)262.2 (1.3)CV%21.538.316.525.4AUClast (h*ng/ml)n6666GM mean (GSD)1699.6 (1.3)1141.8 (2.0)3351.8 (1.2)8492.0 (1.3)CV%24.343.518.326.4AUC0‐inf (h*ng/ml)n6666GM mean (GSD)1818.3 (1.3)1231.8 (1.9)3449.3 (1.2)8619.0 (1.3)CV%21.342.418.526.8AUCtau (h*ng/ml) n 6666GM mean (GSD)1105.6 (1.3)688.2 (1.8)1841.5 (1.2)2622.4 (1.3)CV%21.538.316.625.4 t 1/2 (h) n 6666GM mean (GSD)16.8 (1.1)19.8 (1.4)19.6 (1.1)18.7 (1.2)CV%13.241.29.615.7 λz (1/h) n 6666GM mean (GSD)0.04 (1.1)0.03 (1.4)0.04 (1.1)0.04 (1.2)CV%12.031.19.214.7MRT (h)n6666GM mean (GSD)25.4 (1.0)29.0 (1.1)31.9 (1.1)27.7 (1.0)CV%4.712.16.43.6CLss/F (ml/h)n6666GM mean (GSD)27161.0 (1.3)145323.7 (1.8)40709.3 (1.2)26702.6 (1.3)CV%27.979.718.825.6Vz/F (ml) n 6666GM mean (GSD)656771.4 (1.4)4155877.2 (1.8)1152496.0 (1.1)721356.3 (1.1)CV%34.367.413.012.7 Note: AUC0‐inf is the area under the plasma concentration time curve from time 0 extrapolated to infinity. AUC0‐inf is calculated as the sum of AUClast plus the ratio of the last measurable plasma concentration to the elimination rate constant. AUClast is the area under the plasma concentration time curve, from time 0 to the last measurable non‐zero concentration; AUCtau is the area under the concentration time curve during the dosing interval, from time 0 to tau (10 h in BID and 24 h in OD, following multiple dosing only). BID, twice daily; C avg, average concentration during a dosing interval (following multiple dosing only); CLss/F, apparent plasma clearance of drug after extravascular administration; C max, maximum observed concentration; C min, minimum observed concentration (following multiple dosing only); CV%, coefficient of variation; h, hour; λz, terminal rate constant; GSD, geometric standard deviation; MAD, multiple ascending dose; MRT, mean residence time; N, total number of participants; n, number of participants in the category of interest; NC, not calculated; OD, once daily; PK, pharmacokinetic; t 1/2, apparent first‐order terminal elimination half‐life, calculated as 0.693/Kel; T max, time to reach C max. If the maximum value occurs at more than 1 timepoint, T max is defined as the first timepoint with this value; Vz/F, apparent volume of distribution/bioavailability. MAD part – summary of main PK parameters of SDC‐1801 on day 10 (pharmacokinetic analysis set). Note: AUC0‐inf is the area under the plasma concentration time curve from time 0 extrapolated to infinity. AUC0‐inf is calculated as the sum of AUClast plus the ratio of the last measurable plasma concentration to the elimination rate constant. AUClast is the area under the plasma concentration time curve, from time 0 to the last measurable non‐zero concentration; AUCtau is the area under the concentration time curve during the dosing interval, from time 0 to tau (10 h in BID and 24 h in OD, following multiple dosing only). BID, twice daily; C avg, average concentration during a dosing interval (following multiple dosing only); CLss/F, apparent plasma clearance of drug after extravascular administration; C max, maximum observed concentration; C min, minimum observed concentration (following multiple dosing only); CV%, coefficient of variation; h, hour; λz, terminal rate constant; GSD, geometric standard deviation; MAD, multiple ascending dose; MRT, mean residence time; N, total number of participants; n, number of participants in the category of interest; NC, not calculated; OD, once daily; PK, pharmacokinetic; t 1/2, apparent first‐order terminal elimination half‐life, calculated as 0.693/Kel; T max, time to reach C max. If the maximum value occurs at more than 1 timepoint, T max is defined as the first timepoint with this value; Vz/F, apparent volume of distribution/bioavailability. In both the SAD and MAD parts, urine sample analysis indicated a low renal elimination of SDC‐1801, with GM less than 3.5% of the administered dose over a 24‐h period, indicating low renal clearance of SDC‐1801 primarily through metabolism. In the FE part, following 75 mg SDC‐1801 dosing in both the fed and fasted states, T max observed was 6 and 3 h post‐dose for the fed and fasted states, respectively, GM C max was 90.6 and 82.3 ng/ml (Figure 3C), GM AUC0‐inf was 2641.2 and 2021.4 ng.h/ml, and GM t 1/2 was 18.6 and 18.5 h, respectively. GM Vz/F was 762 171.2 and 992 664.7 ml, and CL/F was 28 389.9 and 37 093.6 ml/h in the fed and fasted states, respectively. The variability associated with the exposure related parameters of C max and AUC0‐inf values was considered low to moderate at 13.7 to 41.7 CV% (Table S11). Pharmacodynamics Some participants had elevated IP‐10 at baseline (pre‐dose day 1). In the SAD part, there was no change in mean IP‐10 levels following a single dose of SDC‐1801; however, in the MAD part, there was a clear reduction at pre‐dose on day 9 (Figure 4A). Percent change from baseline to pre‐dose on day 9, mean, median, interquartile range and range (SDC‐1801 MAD part). (A) IP‐10 (ng/ml) (B) hsCRP (mg/l). BID, twice daily; hsCRP, high‐sensitivity C reactive protein; IP‐10, interferon Gamma induced protein; MAD, multiple ascending dose; OD, once daily; PD, pharmacodynamics. Normal ranges: IP‐10: <300 ng/l; hsCRP: <3 mg/l. In the 30 mg OD group, one participant was excluded from the hsCRP analysis because of an extremely low baseline value (0.1 mg/l) that rose within the normal range to 2.6 mg/l on day 9 (pre‐dose). In the SAD and MAD parts, all participants had hsCRP levels in the normal range (<0.3 mg/ml) 19 at screening and at baseline (pre‐dose day 1), and levels remained within the normal range following administration of single and multiple doses of SDC‐1801. Following multiple doses of 70 mg BID, SDC‐1801, there was a clear reduction in percent change from baseline hsCRP levels by pre‐dose day 9 (Figure 4B). It should be noted that the 100 mg dose had poor drug exposure (Table 3). With increasing SDC‐1801 exposure resulting from multiple dosing, there was an increasing inhibition of phosphorylated STAT (pSTAT)3 and pSTAT5 mean fluorescence index (MFI)) in CD14+ monocytes and CD3+ T cells following ex vivo IFN‐α stimulation (Figure 5A–D), indicating an exposure–effect relationship. Change in flow cytometry count vs. SDC‐1801 concentration for pSTAT3‐PerCP‐Cy5.5 MFI and pSTAT5‐PE MFI (difference between unstimulated and stimulated cell populations in CD14+ monocytes and CD3+ T cells following IFN‐α‐stimulation (MAD part). (A) pSTAT3 in CD14+ monocytes, (B) pSTAT5 in CD14+ monocytes, (C) pSTAT3 in CD3+ T cells and (D) pSTAT5 in CD3+ T cells. IFN‐α, interferon alpha; MAD, multiple ascending dose; MFI, mean fluorescence index; PE, phycoerythrin; PerCP‐Cy5.5, peridinin chlorophyll protein‐Cyanine5.5; pSTAT, phosphorylated signal transducer and activator of transcription. Over the 10 days of dosing with SDC‐1801, there was no evidence of induction or inhibition of CYP3A using 4β‐OHC/cholesterol ratio as a marker. DISCUSSION TYK2 and JAK kinases are integral to cytokine receptor signalling pathways that regulate immune responses, inflammation, and haematopoiesis and are considered a promising therapeutic target. 4 , 5 TYK2 associates with the receptors of IL‐12, IL‐23, type I IFNs and IL‐10 family cytokines, key mediators in the pathogenesis of autoimmune and inflammatory diseases. 5 , 10 JAK1, likewise, is involved in signalling for pro‐inflammatory cytokines such as IL‐6 and IFNs. 1 , 16 CRP, a marker of inflammation elevated in diseases such as diabetes, cancers, cardiovascular and autoimmune diseases, 20 , 21 , 22 is predominantly produced by hepatocytes in response to pro‐inflammatory cytokines, mainly IL‐6 which relies on JAK1 for signal transduction. 23 , 24 Interferon (IFN)‐gamma‐induced protein 10 kDa (IP‐10) is a pro‐inflammatory chemokine and biomarker of immune activation, particularly in IFN‐driven diseases, including autoimmune disorders. 25 IP‐10 production is highly dependent on the JAK1/STAT1 signalling pathway, making it a key downstream indicator of JAK1 activity in inflammation. Clinical reductions in hsCRP and IP‐10 have been observed following selective JAK1 inhibitor treatment, for example, upadacitinib, 26 , 27 and dual TYK2/JAK1 inhibitor treatment, for example, brepocitinib. 16 This first‐in‐human study in healthy adult participants evaluated the safety, PK, and PD of single and multiple doses of SDC‐1801, a selective oral TYK2/JAK1 inhibitor, as well as the effects of food on its PK. SDC‐1801 revealed no safety signals of concern at oral doses ranging from 5 to 150 mg with no clinically significant changes from baseline in clinical laboratory values, vital signs or ECGs. There were no deaths or treatment‐related SAEs, and all TEAEs were of mild or moderate intensity. Headache was the most frequently reported TEAE in the SAD and MAD parts but did not appear to be dose‐ or exposure‐dependent. In the MAD part, one participant had elevated CPK levels on Day 6, peaking on Day 9 when they were diagnosed with treatment‐related TEAEs of moderate rhabdomyolysis and mild myalgia and withdrawn from treatment (100 mg OD SDC‐1801). Levels decreased to normal range by the follow‐up visit. No associated abnormalities of creatinine, hepatic transaminases, troponin T, bilirubin or urine microscopy were reported. Sporadic cases of myalgia and rhabdomyolysis have also been observed with other JAK and TYK2 inhibitors, 15 , 16 , 28 , 29 underscoring the importance of continued surveillance for potential muscle toxicity in the early clinical development of SDC‐1801. In the FE part, the incidence and pattern of TEAEs were similar between fed and fasted states, and no headaches were reported. There were no adverse effects on the C‐SSRS score in participants receiving multiple doses of SDC‐1801. After single and multiple SDC‐1801 dosing, T max ranged between 3 and 5 h; following C max, plasma concentrations declined in a mono to biphasic manner. The GM t 1/2 ranged from 15 to 27 h, supporting once or twice daily dosing. AUC and C max findings showed an inconsistent dose and exposure relationship, likely because of formulation differences in capsule strength and solubility. Administration of SDC‐1801 over the dosing ranges was performed with differing combinations of SDC‐1801 capsule strengths, and inspection of the SDC‐1801 concentration time curves for each of the doses indicated that the 50 mg capsules delivered much lower SDC‐1801 exposure than expected, exemplified by the 100 mg OD dose (Figure 3B). To better understand exposure related to the 50 mg capsule, an alternative capsule configuration was used in the 75 mg OD and 70 mg BID cohorts, replacing the 50 mg capsule with 5 × 10 mg capsules; it was clear that the 10 mg capsules provided better exposure than the 50 mg capsule. Based on these data, PK linearity cannot be concluded; therefore, estimated clearance and volume were considered variable throughout, and dose independent kinetics were not confirmed. Modestly increased exposure seen under fed conditions in the FE part indicates that food may enhance absorption by promoting solubilization. In the MAD part, steady state was approached by day 4, with modest accumulation on day 10 relative to day 1, consistent with t 1/2 and showing no evidence of time‐dependent kinetics. T max remained at 3–5 h post‐dose and variability in exposure at steady state was low to moderate. In the 70 mg BID cohort on day 10, only a single dose of SDC‐1801 was administered, and the day 10 PK profile is shown in Table 3. To understand the effect of the 70 mg BID schedule at steady state, computational PK modelling based on SAD and day 1 MAD data predicted an AUC0–24 of 7092 ng.h/ml. Such a level of exposure is comparable with the AUCt demonstrated by brepocitinib at 100 mg OD, which was 6089 ng.h/ml on day 10 in the MAD cohort. 16 However, in contrast to brepocitinib, SDC‐1801 showed no clinically significant reductions in reticulocytes or neutrophils, and no increase in serum creatinine, believed to be because of brepocitinib inhibiting the renal transporter OCT2. Renal clearance of SDC‐1801 was low with a small fraction of the dose eliminated in the urine (<3.5%), indicating clearance primarily through metabolism. The IC50s for inhibition of CYP3A4, CYP2C9 and CYP2C8 in human liver microsomes are much greater than the measured human plasma concentrations. Using 4β‐OHC/cholesterol ratio as a marker, no induction or inhibition of CYP3A activity was observed across cohorts. Overall, SDC‐1801 is considered to have a low risk of drug–drug interactions via this pathway, because of reversible or time‐dependent CYP inhibition. SDC‐1801 exhibited target engagement consistent with TYK2/JAK1 inhibition. Multiple doses of SDC‐1801 resulted in measurable reductions in serum IP‐10 and hsCRP levels, alongside concentration‐dependent suppression of STAT3 and STAT5 phosphorylation following IFNα challenge of blood samples ex vivo. The safety profile and positive biomarker effects reported in this paper indicate SDC‐1801 could be a potent, more selective, TYK2/JAK1 inhibitor for patients with various inflammatory and autoimmune conditions, and further clinical development is warranted. AUTHOR CONTRIBUTIONS The author contributions listed below apply to the manuscript as a whole and are not specific to individual sections of the article. Chris Brearley contributed to the study conception and protocol development, served as Acting Chief Medical Officer for the sponsor during the study, contributed to interpretation of the data, and was involved in drafting and reviewing the manuscript. John Reader contributed to the study conception and protocol development, contributed to interpretation of the data, and was involved in drafting and reviewing the manuscript. Sam Francis was the principal investigator of the clinical study and contributed to the review and approval of the manuscript. Judi Proctor contributed to data interpretation, data visualisation and presentation, preparation of the initial manuscript draft, and critical review and revision of the manuscript. All authors reviewed and approved the final version of the manuscript. CONFLICT OF INTEREST STATEMENT John Reader is a shareholder in Sareum Holdings PLC, the parent company of Sareum Limited. The authors declare no other conflicts of interest. Supporting information Figure S1: Participant Disposition. Figure S3: Haematology Parameters From Study Day 1 to Follow‐up Visit (MAD Part) (A) Mean Neutrophil Count (B) Mean Haemoglobin (C) Mean Reticulocyte Count (D) Mean Lymphocyte Count A. Appendix 1: Capsule combination and dosing details. Figure S2: Haematology Parameters From Study Day 1 to Follow‐up Visit (MAD Part) (A) Mean Neutrophil Count (B) Mean Haemoglobin (C) Mean Reticulocyte Count (D) Mean Lymphocyte Count. Table S1: SAD Part – Summary of Demographics and Baseline Characteristics (Safety Analysis Set). Table S2: MAD Part – Summary of Demographics and Baseline Characteristics (Safety Analysis Set). Table S3: FE Part – Summary of Demographics and Baseline Characteristics (Safety Analysis Set). Table S4: SAD Part ‐ Summary of TEAEs by SOC and PT (Safety Analysis Set). Table S5: MAD Part – Summary of TEAEs by SOC and PT (Safety Analysis Set). Table S6: FE Part – Summary of TEAEs by SOC and PT (Safety Analysis Set). Table S7: SAD Part – Summary of Haematology Parameters for SDC‐1801 Outside Normal Range (Safety Analysis Set). Table S8: MAD Part – Summary of Haematology Parameters for SDC‐1801 Outside Normal Range (Safety Analysis Set). Table S9: FE Part – Summary of Haematology Parameters for SDC‐1801 Outside Normal Range (Safety Analysis Set). Table S10: MAD Part ‐ Summary of Main PK Parameters of SDC‐1801 on Days 1 and 10 (Pharmacokinetic Analysis Set). Table S11: FE Part – Summary of Main PK Parameters of SDC‐1801 (Pharmacokinetic Analysis Set). ACKNOWLEDGEMENTS Medical writing support was provided by Stacey Maxwell of tranScrip Ltd and was funded by Sareum Limited. The authors thank the clinical staff at Nucleus Network for their support in conducting the study and acknowledge the contributions of PharmaKinetic for assistance with pharmacometric analysis. We also thank the healthy volunteers who participated in the trial. The authors acknowledge the support of the bioanalytical laboratory team at 360Biolabs for processing and analysis of flow cytometry samples. We also thank the data management and statistical teams at S‐cubed Biometrics Ltd for their contributions to the study's analysis and reporting, My Medical Department (MMD) for remote medical monitoring, and Harvest Integrated Research Organization (HIRO) for their contributions to the study monitoring. Brearley C, Francis S, Reader J, Proctor J. First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801. Br J Clin Pharmacol. 2026;92(10):3513‐3526. doi: 10.1002/bcp.70642 The authors confirm that the Principal Investigator for this paper is Sam Francis and that he had direct clinical responsibility for patients. Funding information The study was funded by Sareum Limited. Contributor Information John Reader, Email: jreader@sareum.co.uk. Judi Proctor, Email: judi.proctor@transcrip-group.com. DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request. Some data may not be made available because of privacy or ethical restrictions. REFERENCES Associated Data Supplementary Materials Figure S1: Participant Disposition. Figure S3: Haematology Parameters From Study Day 1 to Follow‐up Visit (MAD Part) (A) Mean Neutrophil Count (B) Mean Haemoglobin (C) Mean Reticulocyte Count (D) Mean Lymphocyte Count A. Appendix 1: Capsule combination and dosing details. Figure S2: Haematology Parameters From Study Day 1 to Follow‐up Visit (MAD Part) (A) Mean Neutrophil Count (B) Mean Haemoglobin (C) Mean Reticulocyte Count (D) Mean Lymphocyte Count. Table S1: SAD Part – Summary of Demographics and Baseline Characteristics (Safety Analysis Set). Table S2: MAD Part – Summary of Demographics and Baseline Characteristics (Safety Analysis Set). Table S3: FE Part – Summary of Demographics and Baseline Characteristics (Safety Analysis Set). Table S4: SAD Part ‐ Summary of TEAEs by SOC and PT (Safety Analysis Set). Table S5: MAD Part – Summary of TEAEs by SOC and PT (Safety Analysis Set). Table S6: FE Part – Summary of TEAEs by SOC and PT (Safety Analysis Set). Table S7: SAD Part – Summary of Haematology Parameters for SDC‐1801 Outside Normal Range (Safety Analysis Set). Table S8: MAD Part – Summary of Haematology Parameters for SDC‐1801 Outside Normal Range (Safety Analysis Set). Table S9: FE Part – Summary of Haematology Parameters for SDC‐1801 Outside Normal Range (Safety Analysis Set). Table S10: MAD Part ‐ Summary of Main PK Parameters of SDC‐1801 on Days 1 and 10 (Pharmacokinetic Analysis Set). Table S11: FE Part – Summary of Main PK Parameters of SDC‐1801 (Pharmacokinetic Analysis Set). Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. Some data may not be made available because of privacy or ethical restrictions.